Striatal remodeling in Parkinson disease

Journal of Pharmacology and Experimental Therapeutics · Published 2026-07-01 · DOI 10.1016/j.jpet.2026.104962

Free full text

Authors (4)

Soren D. Emerson, Chiho Sugimoto, Sarah C. Honeycutt, Erin S. Calipari

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Emerson, S., Sugimoto, C., Honeycutt, S., et al. (2026). Striatal remodeling in Parkinson disease. Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/j.jpet.2026.104962

Related articles

• DSP-2342, a novel 5-hydroxytryptamine 2A/7 receptor antagonist, has therapeutic potential for behavioral and psychological symptoms of dementia · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Structure-based prediction of muscarinic M1/M3 receptor antagonist activity: Curated dataset and scaffold-aware evaluation · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Improving drug delivery to mitigate cisplatin nephrotoxicity · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Preclinical pharmacology of N-pyrrolidino “nitazene” opioids appearing in nonmedical drug markets · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Modulation of morphine tolerance and dependence by pyrroloquinoline quinone in mice: Insights into mechanistic bridge from N-methyl-D-aspartate receptors-calcium/calmodulin-dependent protein kinase II signaling to oxidative neuroinflammation · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Comparative analysis of ligand binding affinities and functional profiles at recombinant human β-adrenergic receptor subtypes 1, 2, and 3 · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• An antidote in arms: A monoclonal antibody intervention to reverse fentanyl-induced respiratory apnea · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Chemotype-Dependent Dissociation of Binding Affinity and Functional Potency in Synthetic Cannabinoids · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Integrating CYP2D6 and MATE1 activities in drug–drug interaction assessment: Insights from newly developed antidepressant drug ammoxetine · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal
• Circumvention of acquired resistance to topoisomerase II-targeted anticancer agents in HL-60 leukemia cells by prevention of intronic polyadenylation · Journal of Pharmacology and Experimental Therapeutics · 2026 · Same journal